TG Therapeutics Q3 total net revenue $165.8M; BRIUMVI net sales $25.1M, net income $113.9M

TG THERAPEUTICS, INC.

2023-Q3 EPS reported $0.19 revenue$189,691,000

BRIUMVI net sales $25.1M in Q3; ~$48.9M cumulative since launch; ~2,200 prescriptions from 500+ providers.
License revenue $140.0M from Neuraxpharm upfront for ex-U.S. commercialization of BRIUMVI in RMS.
Net income $113.9M vs net loss $35.8M YoY; cash position $229.2M as of Sept 30, 2023.
Payor coverage for ~95% of covered lives; permanent J-Code (J2329) effective July 1, 2023.
Company expects existing cash plus BRIUMVI revenues to fund operations into cash flow positivity.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TG THERAPEUTICS, INC. reported three and nine months ended September 30, 2023 results: revenue $165.8 million, net income $113.9 million and $27.1 million.

Period: three and nine months ended September 30, 2023
Revenue: $165.8 million
Net income: $113.9 million and $27.1 million
Result: reported results

Exact text from the filing

Third quarter 2023 total net revenue of $165.8 million

View on SEC.gov

Browse all earnings releases →

TG THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-029660

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.